In line with what we previously studied in acute myeloid leukemia (AML), many transplant centers are implementing maintenance strategies either by pharmaceutical interventions such as FLT3 inhibitors in FLT3 mutant AML and hypomethylating agents, or by cellular therapies, mainly the use of donor lymphocyte infusion (DLI) (7–9). This evidence concerns the gene FLT3 and acute myeloid leukemia.